Guo‐Ming Shi

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma.
  2025 L1 66/100

1 assessed by us (0 reproduced) · 180 not yet assessed — every PubMed paper on record, linked below.

• Norepinephrine promotes tumour cell aggressiveness and NK cell ferroptosis via ADRB2 in intrahepatic cholangiocarcinoma with perineural invasion ↗

  Gut · 2026 · PMID 42009561
  not yet assessed
• FGFR2 fusion-driven CXCL3 downregulation attenuates neutrophil recruitment in intrahepatic cholangiocarcinoma ↗

  Cancer Letters · 2026 · PMID 42409257
  not yet assessed
• Oncolytic virus VG161 in refractory hepatocellular carcinoma ↗

  Nature · 2025 · PMID 40108464
  not yet assessed
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) ↗

  Liver Cancer · 2025 · PMID 41063733
  not yet assessed
• Lysine‐specific demethylase 1 deletion reshapes tumour microenvironment to overcome acquired resistance to anti‐programmed death 1 therapy in liver cancer ↗

  Clinical and Translational Medicine · 2025 · PMID 40356247
  not yet assessed
• First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study ↗

  Signal Transduction and Targeted Therapy · 2025 · PMID 40835595
  not yet assessed
• Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma

  Nature Communications · 2025 · PMID 41387425
  L1 66/100
• Publisher Correction: Oncolytic virus VG161 in refractory hepatocellular carcinoma ↗

  Nature · 2025 · PMID 40269171
  not yet assessed
• Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition ↗

  Hepatology · 2025 · PMID 40194300
  not yet assessed
• Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies ↗

  Gut · 2025 · PMID 41022576
  not yet assessed
• Metagenomic next‐generation sequencing provides a rapid and accurate diagnosis of pathogens in patients undergoing immunosuppressive therapy ↗

  Clinical and Translational Discovery · 2025
  not yet assessed
• A noninvasive and highly efficient epigenetic predictive model for efficacy of the GOLP regimen in patients with intrahepatic cholangiocarcinoma ↗

  Cancer Letters · 2025 · PMID 40651656
  not yet assessed
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma ↗

  Nature Communications · 2024 · PMID 38245530
  not yet assessed
• Application of a single-cell-RNA-based biological-inspired graph neural network in diagnosis of primary liver tumors ↗

  Journal of Translational Medicine · 2024 · PMID 39354613
  not yet assessed
• ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC). ↗

  Journal of Clinical Oncology · 2024
  not yet assessed
• Correction: Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis ↗

  Molecular Cancer · 2024 · PMID 38424621
  not yet assessed
• Novel Oncolytic Virus VG161 in Hepatocellular Carcinoma Patients Refractory to Standard Systemic Therapies ↗

  Research Square · 2024
  not yet assessed
• Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition) ↗

  Liver Cancer · 2023 · PMID 37901768
  not yet assessed
• Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study ↗

  Signal Transduction and Targeted Therapy · 2023 · PMID 36928584
  not yet assessed
• Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis ↗

  Cell Death and Disease · 2023 · PMID 36732324
  not yet assessed
• Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version) ↗

  Journal of Clinical and Translational Hepatology · 2023 · PMID 38161496
  not yet assessed
• Autophagy suppression facilitates macrophage M2 polarization via increased instability of NF-κB pathway in hepatocellular carcinoma ↗

  International Immunopharmacology · 2023 · PMID 37494837
  not yet assessed
• 105P A phase II study of SHR-1316 plus IBI310 in patients with advanced intrahepatic cholangiocarcinoma after failure of first-line therapy ↗

  Annals of Oncology · 2023
  not yet assessed
• Data from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure Legend from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Tables 1-3 from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Data from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure Legend from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Tables 1-3 from Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Data from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Supplementary Figure Legend from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Data from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Data from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Data from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Data from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure Legend from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation ↗

  2023
  not yet assessed
• Data from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-2, Tables 1-4 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Figure Legends 1-2, Tables 1-4 from Metadherin Promotes Hepatocellular Carcinoma Metastasis through Induction of Epithelial–Mesenchymal Transition ↗

  2023
  not yet assessed
• Supplementary Figure 2 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Methods, Tables 1-6, Figure Legends 1-4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Methods, Tables 1-6, Figure Legends 1-4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 4 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 2 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figures and methods from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S2 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S7 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S6 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S5 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S3 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S1 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S4 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure Legend, Tables 1 - 2 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Table S2 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S1 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S4 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Supplementary Figures and methods from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S6 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S3 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S7 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Table S5 from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• Supplementary Figure 1 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure Legend, Tables 1 - 2 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 2 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 3 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Figure 4 from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Data from CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery ↗

  2023
  not yet assessed
• Data from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Data from CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery ↗

  2023
  not yet assessed
• Data from Margin-Infiltrating CD20<sup>+</sup> B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Supplementary Data from CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery ↗

  2023
  not yet assessed
• Supplementary Data from CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery ↗

  2023
  not yet assessed
• [Autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma with severe renal impairment: a report of 5 cases and literature review]. ↗

  PubMed · 2023 · PMID 37749041
  not yet assessed
• Data from CXCR6 Upregulation Contributes to a Proinflammatory Tumor Microenvironment That Drives Metastasis and Poor Patient Outcomes in Hepatocellular Carcinoma ↗

  2023
  not yet assessed
• Data from Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  2023
  not yet assessed
• [Daratumumab maintenance after autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma]. ↗

  PubMed · 2023 · PMID 38503525
  not yet assessed
• Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma ↗

  Gut Microbes · 2022 · PMID 36563106
  not yet assessed
• Proteogenomic characterization of cholangiocarcinoma ↗

  Hepatology · 2022 · PMID 35716043
  not yet assessed
• Ten‐eleven translocation‐2 inactivation restrains IL‐10‐producing regulatory B cells to enable antitumor immunity in hepatocellular carcinoma ↗

  Hepatology · 2022 · PMID 35243663
  not yet assessed
• The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion ↗

  Hepatology International · 2022 · PMID 36418844
  not yet assessed
• Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying <i>FGFR2</i> fusions or rearrangements: A phase <scp>II</scp> study ↗

  Cancer Medicine · 2022 · PMID 36127767
  not yet assessed
• Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching analysis ↗

  Surgical Endoscopy · 2022 · PMID 36076103
  not yet assessed
• Apparent Diffusion Coefficient <scp>MRI</scp> Shows Association With Early Progression of Unresectable Intrahepatic Cholangiocarcinoma With Combined Targeted‐Immunotherapy ↗

  Journal of Magnetic Resonance Imaging · 2022 · PMID 35488518
  not yet assessed
• Contrast-enhanced MRI could predict response of systemic therapy in advanced intrahepatic cholangiocarcinoma ↗

  European Radiology · 2022 · PMID 35298678
  not yet assessed
• Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures ↗

  Hepatology International · 2022 · PMID 36258065
  not yet assessed
• Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges ↗

  Journal of Oncology · 2022 · PMID 36405248
  not yet assessed
• 1702P Comutations in DNA damage repair pathway and its correlations with potential biomarkers for colorectal cancer immunotherapy in a Chinese cohort ↗

  Annals of Oncology · 2022
  not yet assessed
• Future liver volume combined with platelet count predicts liver failure after major hepatectomy ↗

  The Surgeon · 2022 · PMID 35283025
  not yet assessed
• Molecular Features and Clinical Implications of Perineural Invasion in Intrahepatic Cholangiocarcinoma ↗

  SSRN Electronic Journal · 2022
  not yet assessed
• CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity ↗

  Molecular Cancer · 2021 · PMID 33985545
  not yet assessed
• Quantitative acetylome analysis reveals histone modifications that may predict prognosis in hepatitis B‐related hepatocellular carcinoma ↗

  Clinical and Translational Medicine · 2021 · PMID 33783990
  not yet assessed
• Simulation of portal/hepatic vein associated remnant liver ischemia/congestion by three-dimensional visualization technology based on preoperative CT scan ↗

  Annals of Translational Medicine · 2021 · PMID 34268369
  not yet assessed
• Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. ↗

  Journal of Clinical Oncology · 2021
  not yet assessed
• Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma. ↗

  Journal of Clinical Oncology · 2021
  not yet assessed
• Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) ↗

  Liver Cancer · 2020 · PMID 33442540
  not yet assessed
• Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma ↗

  Molecular Cancer · 2020 · PMID 32593303
  not yet assessed
• Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis ↗

  Molecular Cancer · 2020 · PMID 32430013
  not yet assessed
• TET2 promotes anti‐tumor immunity by governing G‐MDSCs and CD8+ T‐cell numbers ↗

  EMBO Reports · 2020 · PMID 32929842
  not yet assessed
• Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma ↗

  Annals of Translational Medicine · 2020 · PMID 32309351
  not yet assessed
• A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study ↗

  Surgery · 2020 · PMID 32113581
  not yet assessed
• Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma? ↗

  Hepatobiliary & pancreatic diseases international · 2020 · PMID 33160852
  not yet assessed
• Increased Serum Type I Interferon Level May Predict Outcome in Hepatocellular Carcinoma Patients Treated with Radiotherapy ↗

  International Journal of Radiation Oncology*Biology*Physics · 2020
  not yet assessed
• Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer

  DOAJ (DOAJ: Directory of Open Access Journals) · 2020
  not yet assessed
• Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study. ↗

  Journal of Clinical Oncology · 2020
  not yet assessed
• Deep learning to develop transcriptomic model for survival prediction in TCGA patients with hepatocellular carcinoma. ↗

  Journal of Clinical Oncology · 2020
  not yet assessed
• Additional file 2 of Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis ↗

  Open MIND · 2020
  not yet assessed
• Additional file 3 of Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis ↗

  Figshare · 2020
  not yet assessed
• Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma ↗

  Gut · 2019 · PMID 31358576
  not yet assessed
• Circular RNA circTRIM33–12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression ↗

  Molecular Cancer · 2019 · PMID 31153371
  not yet assessed
• Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma ↗

  Journal of Experimental & Clinical Cancer Research · 2019 · PMID 30836988
  not yet assessed
• Lymphoid‐specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression ↗

  Cancer Science · 2019 · PMID 31066149
  not yet assessed
• HNRNPAB‐regulated lncRNA‐ELF209 inhibits the malignancy of hepatocellular carcinoma ↗

  International Journal of Cancer · 2019 · PMID 31090062
  not yet assessed
• Predicting overall survival of patients with hepatocellular carcinoma using a three‐category method based on DNA methylation and machine learning ↗

  Journal of Cellular and Molecular Medicine · 2019 · PMID 30784182
  not yet assessed
• eIF3a mediates HIF1α-dependent glycolytic metabolism in hepatocellular carcinoma cells through translational regulation. ↗

  PubMed · 2019 · PMID 31218114
  not yet assessed
• Additional file 3: of Circular RNA circTRIM33â 12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression ↗

  INDIGO (University of Illinois at Chicago) · 2019
  not yet assessed
• Additional file 7: of Circular RNA circTRIM33â 12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression ↗

  Figshare · 2019
  not yet assessed
• Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer ↗

  Nature · 2018 · PMID 30022161
  not yet assessed
• Canonical Wnt Signaling Remodels Lipid Metabolism in Zebrafish Hepatocytes following Ras Oncogenic Insult ↗

  Cancer Research · 2018 · PMID 30065049
  not yet assessed
• NOD-like receptor X1 functions as a tumor suppressor by inhibiting epithelial-mesenchymal transition and inducing aging in hepatocellular carcinoma cells ↗

  Journal of Hematology & Oncology · 2018 · PMID 29482578
  not yet assessed
• The long noncoding RNA NORAD enhances the TGF‐β pathway to promote hepatocellular carcinoma progression by targeting miR‐202‐5p ↗

  Journal of Cellular Physiology · 2018 · PMID 30537113
  not yet assessed
• Invasive potential of hepatocellular carcinoma is enhanced by loss of selenium-binding protein 1 and subsequent upregulation of CXCR4. ↗

  PubMed · 2018 · PMID 30034941
  not yet assessed
• Dexamethasone for postoperative hyperbilirubinemia in patients after liver resection: An open-label, randomized controlled trial ↗

  Surgery · 2018 · PMID 30348460
  not yet assessed
• Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition. ↗

  PubMed · 2018 · PMID 30662608
  not yet assessed
• Prognostic value of WHO histopathological classification and serum levels of AFP and CA19-9 in post-surgical patients with combined hepatocellular carcinoma-cholangiocarcinoma

  2018
  not yet assessed
• 5-Hydroxymethylcytosines from Circulating Cell-free DNA as Diagnostic and Prognostic Markers for Hepatocellular Carcinoma ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2018
  not yet assessed
• The prognostic impact of microvascular invasion on patients with intrahepatic cholangiocarcinoma after R0 resections ↗

  Zhonghua gan-dan waike zazhi · 2018
  not yet assessed
• lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial&amp;ndash;mesenchymal transition in melanoma cells

  DOAJ (DOAJ: Directory of Open Access Journals) · 2018
  not yet assessed
• Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma ↗

  Cell Death and Disease · 2017 · PMID 29235470
  not yet assessed
• Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis ↗

  Journal of Cancer · 2017 · PMID 29151974
  not yet assessed
• Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B ↗

  BMC Cancer · 2017 · PMID 28095820
  not yet assessed
• Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma ↗

  Journal of Gastrointestinal Surgery · 2017 · PMID 28510795
  not yet assessed
• Mortalin promotes cell proliferation and epithelial mesenchymal transition of intrahepatic cholangiocarcinoma cells in vitro ↗

  Journal of Clinical Pathology · 2017 · PMID 28096273
  not yet assessed
• Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma ↗

  Infectious Agents and Cancer · 2017 · PMID 28559922
  not yet assessed
• UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2 ↗

  Oncotarget · 2016 · PMID 27121050
  not yet assessed
• BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma ↗

  International Journal of Immunopathology and Pharmacology · 2015 · PMID 25816404
  not yet assessed
• Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies ↗

  BMC Cancer · 2015 · PMID 26526500
  not yet assessed
• Mitogen‐activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial‐mesenchymal transition ↗

  Hepatology · 2015 · PMID 26340507
  not yet assessed
• Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. ↗

  PubMed · 2015 · PMID 25628953
  not yet assessed
• Prediction of Post-Operative Liver Dysfunction by Serum Markers of Liver Fibrosis in Hepatocellular Carcinoma ↗

  PLoS ONE · 2015 · PMID 26501145
  not yet assessed
• Ubiquitin‐specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor‐interacting protein 12 and promotes hepatocellular carcinoma progression ↗

  Hepatology · 2014 · PMID 25557975
  not yet assessed
• Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma ↗

  Tumor Biology · 2014 · PMID 25480415
  not yet assessed
• Comprehensive Multiple Molecular Profile of Epithelial Mesenchymal Transition in Intrahepatic Cholangiocarcinoma Patients ↗

  PLoS ONE · 2014 · PMID 24816558
  not yet assessed
• Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study ↗

  British Journal of Radiology · 2014 · PMID 24452058
  not yet assessed
• Detection and clinical significance of HbA1c, Hcy and BNP in patients with diabetic cardiomyopathy

  Clinical Education of General Practice · 2014
  not yet assessed
• Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma ↗

  PLoS ONE · 2013 · PMID 23349941
  not yet assessed
• Low Level of Low-Density Lipoprotein Receptor-Related Protein 1 Predicts an Unfavorable Prognosis of Hepatocellular Carcinoma after Curative Resection ↗

  PLoS ONE · 2012 · PMID 22427881
  not yet assessed
• CD151 Amplifies Signaling by Integrin α6β1 to PI3K and Induces the Epithelial–Mesenchymal Transition in HCC Cells ↗

  Gastroenterology · 2011 · PMID 21320503
  not yet assessed
• Profiling of the Tetraspanin CD151 Web and Conspiracy of CD151/Integrin β1 Complex in the Progression of Hepatocellular Carcinoma ↗

  PLoS ONE · 2011 · PMID 21961047
  not yet assessed
• CD151 Modulates Expression of Matrix Metalloproteinase 9 and Promotes Neoangiogenesis and Progression of Hepatocellular Carcinoma ↗

  Hepatology · 2010 · PMID 20578262
  not yet assessed
• Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients ↗

  Cancer · 2010 · PMID 20715158
  not yet assessed
• CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery ↗

  Clinical Cancer Research · 2009 · PMID 19706825
  not yet assessed
• Liver‐intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus‐positive hepatocellular carcinoma ↗

  Cancer · 2009 · PMID 19626651
  not yet assessed
• A Comparison of Hepatic Mucinous Cystic Neoplasms With Biliary Intraductal Papillary Neoplasms ↗

  Clinical Gastroenterology and Hepatology · 2009 · PMID 19245849
  not yet assessed
• Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma # ↗

  Hepatology · 2008 · PMID 19065669
  not yet assessed
• Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials ↗

  Journal of Cancer Research and Clinical Oncology · 2008 · PMID 18470535
  not yet assessed
• Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection ↗

  Clinical Cancer Research · 2008 · PMID 18559605
  not yet assessed
• Osteopontin Combined with CD44, a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative Resection ↗

  The Oncologist · 2008 · PMID 18997126
  not yet assessed
• Clinical analysis of 13 cases of lichen striatus

  Journal of Dermatology and Venereology · 2005
  not yet assessed
• [Development of rheumatology in the recent decade in China]. ↗

  PubMed · 1999 · PMID 12797324
  not yet assessed
• [Progresses in rheumatology in China, 1996]. ↗

  PubMed · 1996 · PMID 9275566
  not yet assessed
• [Surgical treatment of benign stenosis of the esophagus]. ↗

  PubMed · 1995 · PMID 7656709
  not yet assessed
• [Analysis of the multidrug resistance MDR1 gene expression in clinical leukemia with RT-PCR]. ↗

  PubMed · 1995 · PMID 8556928
  not yet assessed